ly2969822
Small moleculeexperimental
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2013 (NCT02018887)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
GRM3 agonist
From poster: orally bioavailable prodrug for a potent, selective mGlu2/3 receptor agonist, have no more information.
GRM2 agonist
From poster: orally bioavailable prodrug for a potent, selective mGlu2/3 receptor agonist, have no more information.
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3545270 ↗
Also known as
- ly2969822
- ly2969822
- ly-2969822
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02018887 | Phase 1 | Dec 1, 2013 | Eli Lilly |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eli Lilly | For profit | 1 | 1 | 1 | 2013 |
1 organizations
Page 1 / 1